Evaluating and managing irritability and aggression in children and adolescents with autism spectrum disorder: An algorithm

被引:0
作者
Ooi, Aaron [1 ,2 ]
Banno, Brian [1 ,3 ]
McFee, Kristen [1 ]
Elbe, Dean [4 ,5 ,6 ]
Friedlander, Robin [1 ,7 ,8 ]
机构
[1] BC Childrens Hosp, Neuropsychiat Clin, Vancouver, BC, Canada
[2] Rotorua Hosp, Dept Paediat, Rotorua, New Zealand
[3] Univ British Columbia, Div Child & Adolescent Psychiat, Dept Psychiat, Fac Med, Vancouver, BC, Canada
[4] BC Childrens Hosp, Dept Pharm, Vancouver, BC, Canada
[5] BC Womens Hosp & Hlth Ctr, Vancouver, BC, Canada
[6] BC Childrens Hosp, Child & Adolescent Mental Hlth Programs, Vancouver, BC, Canada
[7] Univ British Columbia, Neurodev Disorders Program, Vancouver, BC, Canada
[8] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
来源
BRITISH COLUMBIA MEDICAL JOURNAL | 2023年 / 65卷 / 08期
关键词
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SELF-INJURIOUS-BEHAVIOR; DOUBLE-BLIND; PEDIATRIC-PATIENTS; PHARMACOLOGICAL-TREATMENT; CHALLENGING BEHAVIORS; OPEN-LABEL; PLACEBO; RISPERIDONE; SYMPTOMS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A range of maladaptive behaviors, including irritability and aggression, are often encountered in autism spectrum disorder. Challenges in complex clinical decision making and management exist, and off-label antipsychotic prescribing is increasing in Canada. A literature review of various treatments, limited to randomized controlled trials in the pediatric population, was used to develop an algorithm for evaluating and managing irritability and aggression in autism spectrum disorder within a Canadian context, which is supported by expert consensus. Holistic consideration of biomedical, psychiatric, psychosocial, environmental, and developmental factors that affect behavior is emphasized. The algorithm highlights the multifactorial contributors to irritability and aggression in autism spectrum disorder and reserves the use of antipsychotic medication for managing the most severe and refractory cases. A comprehensive evaluation of the drivers of behavior when addressing irritability and aggression in autism spectrum disorder is crucial to identify treatable contributors and institute appropriate management.
引用
收藏
页码:291 / 301
页数:11
相关论文
共 50 条
  • [31] Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
    Scahill, Lawrence
    McCracken, James T.
    King, Bryan H.
    Rockhill, Carol
    Shah, Bhavik
    Politte, Laura
    Sanders, Roy
    Minjarez, Mendy
    Cowen, Jennifer
    Mullett, Jennifer
    Page, Chris
    Ward, Denise
    Deng, Yanhong
    Loo, Sandra
    Dziura, James
    McDougle, Christopher J.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2015, 172 (12) : 1197 - 1206
  • [32] The Assessment and Treatment of Sleep Abnormalities in Children and Adolescents with Autism Spectrum Disorder: A Review
    Rana, Mandeep
    Kothare, Sanjeev
    DeBassio, William
    [J]. JOURNAL OF THE CANADIAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 30 (01) : 25 - 35
  • [33] Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders
    Canitano, Roberto
    [J]. CLINICAL NEUROPHARMACOLOGY, 2015, 38 (05) : 177 - 182
  • [34] Risperidone for children and adolescents with autism spectrum disorder: a systematic review
    Maneeton, Narong
    Maneeton, Benchalak
    Putthisri, Suwannee
    Woottiluk, Pakapan
    Narkpongphun, Assawin
    Srisurapanont, Manit
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 1811 - 1820
  • [35] Face Memory Deficits in Children and Adolescents with Autism Spectrum Disorder
    Suri, Kirin
    Lewis, Michael
    Minar, Nicholas
    Willson, Emily
    Ace, Jessica
    [J]. JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT, 2021, 43 (01) : 108 - 118
  • [36] Care of Children with Autism Spectrum Disorder
    Ellerbeck, Kathryn
    Smith, Catherine
    Courtemanche, Andrea
    [J]. PRIMARY CARE, 2015, 42 (01): : 85 - +
  • [37] Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects
    Vanwong, Natchaya
    Srisawasdi, Pornpen
    Ngamsamut, Nattawat
    Nuntamool, Nopphadol
    Puangpetch, Apichaya
    Chamkrachangpada, Bhunnada
    Hongkaew, Yaowaluck
    Limsila, Penkhae
    Kittitharaphan, Wiranpat
    Sukasem, Chonlaphat
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 7
  • [38] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders
    Houghton, Richard
    van den Bergh, Joop
    Law, Kiely
    Liu, Yutong
    de Vries, Frank
    [J]. AUTISM RESEARCH, 2021, 14 (08) : 1800 - 1814
  • [39] Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
    Ichikawa, Hironobu
    Mikami, Katsunaka
    Okada, Takashi
    Yamashita, Yushiro
    Ishizaki, Yuko
    Tomoda, Akemi
    Ono, Hiroaki
    Usuki, Chiharu
    Tadori, Yoshihiro
    [J]. CHILD PSYCHIATRY & HUMAN DEVELOPMENT, 2017, 48 (05) : 796 - 806
  • [40] Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance
    Sugimoto, Yuna
    Yamamura, Kayo
    Takayama, Tomoyo
    Fukuta, Yasuhiko
    Aoki, Kazuo
    Mikami, Katsunaka
    Tomoda, Akemi
    [J]. BMC PSYCHIATRY, 2021, 21 (01)